Ecosystem
Beta Site
Search Results
151 items found for "Systemic treatment"
- S1P Signaling Genes as Prominent Drivers of BCR-ABL1-Independent Imatinib Resistance and Six Herbal Compounds as Potential Drugs for Chronic Myeloid Leukemia
Published date July 1, 2024 Abstract "Imatinib (IM), a breakthrough in chronic myeloid leukemia (CML) treatment
- Minireview: functional roles of tissue kallikrein, kinins, and kallikrein-related peptidases in lung cancer
lung cancer Published date July 3, 2023 Abstract "Despite campaigns and improvements in detection and treatment
- Single cell G-protein coupled receptor profiling of Transcription factor 21 expressing activated kidney fibroblasts
kidneys of mice with UUO or diabetes or injected with adriamycin or folic acid, whereas renin angiotensin system
- Ovarian cancer G protein-coupled receptor 1 (OGR1) deficiency exacerbates crystal deposition and kidney injury in oxalate nephropathy in female mice
In this setting, OGR1 KO mice displayed an increased activation of the immune system and a higher production
- Identification of a G-protein coupled receptor-related gene signature through bioinformatics analysis to construct a risk model for ovarian cancer prognosis
2024 Abstract " Background: Ovarian cancer (OV) is a common malignant tumor of the female reproductive system
- Ep 60 with Dr. Josephine (Pina) Cardarelli
receptor project, licensed to AstraZeneca (Saphnelo™ Anifrolumab) that has just received FDA approval for systemic
- CaaX-motif-adjacent residues influence G protein gamma (Gγ) prenylation under suboptimal conditions
statins as Ras oncogene inhibitors and the failure of using prenyltransferase inhibitors in cancer treatment
- Vasoactive intestinal peptide receptor 2 signaling promotes breast cancer cell proliferation by enhancing the ERK pathway
Treatment with KS-133, a VIPR2-selective antagonist peptide, significantly inhibited VIP-induced cell
- Deciphering a GPCR-lncRNA-miRNA Nexus: Identification of an Aberrant Therapeutic Target in Ovarian Cancer
Thus, our results identify LPAR-UCA1-let-7 axis as a novel avenue for targeted treatment strategies."
- Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia
Patients who responded to treatment had elevated mitochondrial function and OXPHOS.
- A disturbed metabolite-GPCR axis is associated with microbial dysbiosis in IBD patients: Potential role of GPR109A in macrophages
The treatment with β-hydroxybutyrate increased gene expression of GPR109A, CD86, IL1B and NOS2 in U937
- Lactate receptor GPR81 drives breast cancer growth and invasiveness through regulation of ECM properties and Notch ligand DLL4
findings reveal a new GPR81-driven mechanism in breast cancer and substantiate GPR81 as a promising treatment
- Molecular docking and dynamics simulation studies uncover the host-pathogen protein-protein interactions in Penaeus vannamei and Vibrio parahaemolyticus
Vibrio spp. infection on shrimps, which then can be used to assist in the development of effective treatment
- The orphan G protein-coupled receptor 141 expressed in myeloid cells functions as an inflammation suppressor
physiological functions of many GPCRs and the involvement of them in autoimmune diseases of the central nervous system
- Involvement of Protease-Activated Receptor2 Pleckstrin Homology Binding Domain in Ovarian Cancer: Expression in Fallopian Tubes and Drug Design
involvement of PAR PH binding motif signaling in ovarian cancer and Pc(4-4) as a potential therapy treatment
- Stimulation of ectopically expressed muscarinic receptors induces IFN-γ but suppresses IL-2 production by inhibiting activation of pAKT pathways in primary T cells
Clozapine treatment induced high IFN-γ, CD69, and CD25 expression, but surprisingly did not induce substantial
- Comparison of infectious complications with BCMA-directed therapies in multiple myeloma
During periods of treatment-emergent hypogammaglobulinemia, BsAb recipients had higher infection rates
- GPCR Retreat 2023 | Dr. GPCR Ecosystem
scientists working in the arenas of structure and signaling, neuroscience, cancer, translational and model systems
- GPR37 expression as a prognostic marker in gliomas: a bioinformatics-based analysis
The possible biological mechanisms of GPR37 provide novel insights into the clinical diagnosis and treatment
- Investigating isoform switching in RHBDF2 and its role in neoplastic growth in breast cancer
protease known as iRhom2 encoded by the gene RHBDF2 can be considered an important target for cancer treatment
- RGS20 promotes non-small cell lung carcinoma proliferation via autophagy activation and inhibition of the PKA-Hippo signaling pathway
RGS20 as a promising novel molecular marker and a target for future targeted therapies in lung cancer treatment
- Removing the GPCR-mediated brake on exocytosis enhances insulin action, promotes adipocyte browning, and protects against diet-induced obesity
Current areas of interest include Protease Activated Receptor signaling in the cardiovascular system
- Ep 50 with Dr. Thomas P. Sakmar
strategies to express, reconstitute and assay engineered GPCRs using the visual pigment rhodopsin as a model system
- Ep 148 with Dr Arthur Christopoulos
Arthur shared his insights into the unique grant funding system in Australia, the importance of impact discoveries, the role of biotech, and the need for efficiency and process development in university systems
- Ep 149 with Dr Arthur Christopoulos
Arthur shared his insights into the unique grant funding system in Australia, the importance of impact discoveries, the role of biotech, and the need for efficiency and process development in university systems
- Receptor autoantibodies: Associations with cardiac markers, histology, and function in human non-ischaemic heart failure
Correlation of alterations of GPCR autoantibodies with markers of cardiac or systemic inflammation or
- GPR68-ATF4 signaling is a novel prosurvival pathway in glioblastoma activated by acidic extracellular microenvironment
stands as a formidable challenge in oncology because of its aggressive nature and severely limited treatment
- Ep 150 with Dr GPCR Team
Further down the track, he aims to apply this knowledge to develop novel chemical treatments for neuronal
